By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
News for IndiaNews for IndiaNews for India
  • Home
  • Posts
  • Search Page
  • About us
Reading: Q1 results 2026: RVNL to MRF among companies to declare Q1 results today; full list here | Stock Market News
Share
Font ResizerAa
News for IndiaNews for India
Font ResizerAa
  • Economics
  • Business
  • Home
  • Categories
    • Business
    • Economics
  • About us
  • Sitemap
Follow US
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
News for India > Business > Q1 results 2026: RVNL to MRF among companies to declare Q1 results today; full list here | Stock Market News
Business

Q1 results 2026: RVNL to MRF among companies to declare Q1 results today; full list here | Stock Market News

Last updated: August 11, 2026 8:24 am
1 hour ago
Share
SHARE


Contents
MRF Q1 results 2026 previewZydus Lifesciences Q1 results 2026 preview

Q1 results 2026: More than 300 companies are scheduled to release their financial results for the quarter ending on 30 June 2026 (Q1 results 2026) on Tuesday, 11 August, amid ongoing earnings season.

Rail Vikas Nigam, MRF, Zydus Lifesciences, NBCC (India), Senco Gold, Manappuram Finance are the companies to report their Q1 results FY27 today.

On Monday, the Indian stock market ended largely flat, with the benchmark Nifty 50 closing below the 24,600 mark. The Sensex edged up 43.27 points, or 0.06%, to finish at 78,542.44, while the Nifty 50 gained 13.15 points, or 0.05%, to settle at 24,583.80.

MRF Q1 results 2026 preview

Brokerage firm Kotak Institutional Equities expect MRF’s revenues to increase by 12% on a YoY basis, led by double-digit yoy volume growth in OEM and export segment volumes and high-single-digit yoy volume growth in replacement segment.

It further expects EBITDA margin to decline by 400 bps QoQ to 12% in 1QFY27 mainly on account of RM headwinds and RM basket to remain 15-16% inflationary on a qoq basis.

Zydus Lifesciences Q1 results 2026 preview

Brokerage firm Motilal Oswal expects Zydus Lifesciences’ revenue to maintain healthy double-digit growth, driven by strong performance in DF, Europe and emerging markets and DF is likely to grow 14% YoY, led by continued strength in chronic therapies and differentiated launches.

It further anticipates EBITDA margin expected at 25.6%, aided by a favorable product mix despite limited contribution from g-Revlimid.

Progress on the Assertio acquisition and synergy realization from the Amplitude portfolio will remain key monitorables, it said.

Disclaimer: This story is for educational purposes only. Please consult with an investment advisor before making any investment decisions.



Source link

You Might Also Like

Access Denied

Access Denied

Access Denied

Access Denied

Access Denied

TAGGED:Indian stock marketmrfMRF Q1 results 2026 previewnbcc indiaQ1 earnings 2026Q1 earnings 2026 todayQ1 earnings FY27Q1 earnings FY27 todayq1 results 2026Q1 results 2026 todayQ1 results FY27Q1 results FY27 todRail Vikas NigamSenco GoldStock market todayzydus lifesciencesZydus Lifesciences Q1 results 2026 preview
Share This Article
Facebook Twitter Email Print
Previous Article Shankesh Jewellers IPO price band fixed at ₹88- ₹93 per share; issue date, key details here | Stock Market News
Next Article Access Denied
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

We influence 20 million users and is the number one business and technology news network on the planet.

Find Us on Socials

News for IndiaNews for India
© Wealth Wave Designed by Preet Patel. All Rights Reserved.
  • BUSINESS